Why did UnitedHealth Group (UNH) stock move recently?

On 7/21/2026, UnitedHealth Group moved +3.5% — UnitedHealth Group's stock rose on continued positive reaction to its Q2 2026 earnings beat (revenue $112B, adjusted EPS $6.38) and raised full-year 2026 adjusted EPS guidance to $19.50-$20.00, supported by Optum growth and managed care strength. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is UnitedHealth Group (UNH) overvalued or fairly valued?

MarketChacha shows UnitedHealth Group's valuation in context — a trailing P/E of about 20.6, a forward P/E of about 17.7, a price-to-book of about 3.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does UnitedHealth Group's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.49×) from reported figures — education, not a rating.

What is UnitedHealth Group's revenue?

UnitedHealth Group reported revenue of $447.6B for FY2025, with net profit of $12.1B, per official filings.

What is the share price of UnitedHealth Group (UNH)?

UnitedHealth Group last traded at $397.14 (-0.9% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

UnitedHealth Group

UNH · NYSE · Healthcare · United States

Snapshot

TickerUNH

ExchangeNYSE

SectorHealthcare

IndustryHealthcare Plans

CountryUnited States

CEOMr. Timothy John Noel

Employees390,000

HeadquartersEden Prairie, United States

Websitewww.unitedhealthgroup.com

Filings tracked23

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. It operates through four segments: Optum Health, Optum Insight, Optum Rx; and UnitedHealthcare. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services with patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, public entities, life sciences companies and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease and drug therapy management. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; Medicaid plans, including Temporary Assistance to Needy Families; Children's Health Insurance Programs; Dual SNPs; Long-Term Services and Supports; Aged, Blind and Disabled; and other federal, state, and community health care programs. and health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. UnitedHealth Group Incorporated was founded in 1974 and is based in Eden Prairie, Minnesota.

Who owns it

Insiders0.2%
Institutions89.7%
Public & other10.0%

4,378 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.56%
Vanguard Capital Management LLC6.61%
State Street Corporation5.08%
Capital World Investors3.33%
FMR, LLC3.12%
Vanguard Portfolio Management LLC2.73%
Price (T.Rowe) Associates Inc2.58%
Geode Capital Management, LLC2.42%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 3.3 points over the period — profitability is trending down.

Cash conversion1.49×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend6.0% → 2.7%

Margin has compressed by about 3.3 points over the period — profitability is trending down.

Growth qualityrev 10% · PAT -27%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $111.3B · EPS 2.14

Est. earnings growth +1.3%

Next fiscal year

Rev $459.4B · EPS 22.44

Est. earnings growth +13.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$447.6B

Net margin

2.7%

ROE

12.0%

Revenue CAGR (2y)

+9.7%

Profit CAGR (2y)

-26.6%

EPS (FY2025)

13.23

Net profit (FY2025)

$12.1B

Ask MarketChacha about UNH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 21, 2026
UnitedHealth Group's stock rose on continued positive reaction to its Q2 2026 earnings beat (revenue $112B, adjusted EPS $6.38) and raised full-year 2026 adjusted EPS guidance to $19.50-$20.00, supported by Optum growth and managed care strength.
source 1 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about UNH

Why did CVS Health drop ~6% after a big Q2 beat AND raised guidance?c/usmarkets · 8/5/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$447.6B	$12.1B	13.23	2.7%	12.0%
FY2024	$400.3B	$14.4B	15.51	3.6%	14.7%
FY2023	$371.6B	$22.4B	23.86	6.0%	23.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$112.0B	$5.5B	6.04	4.9%
2026Q1	$111.7B	$6.3B	6.90	5.6%
2025Q3	$113.2B	$2.3B	2.59	2.1%
2025Q2	$111.6B	$3.4B	3.74	3.1%
2025Q1	$109.6B	$6.3B	6.85	5.7%
2024Q3	$100.8B	$6.1B	6.51	6.0%
2024Q2	$98.9B	$4.2B	4.54	4.3%
2024Q1	$99.8B	$-1.4B	-1.53	-1.4%
2023Q3	$92.4B	$5.8B	6.24	6.3%
2023Q2	$92.9B	$5.5B	5.82	5.9%
2023Q1	$91.9B	$5.6B	5.95	6.1%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/10/2026
8-K — Results of operations, Exhibits
SEC7/16/2026material
8-K — Shareholder vote results
SEC6/5/2026material
8-K — Reg FD disclosure
SEC5/11/2026material
10-Q filing
SEC5/5/2026
8-K — Results of operations, Exhibits
SEC4/21/2026material
8-K — Reg FD disclosure
SEC3/9/2026material
10-K filing
SEC3/2/2026
8-K — Executive/director change
SEC3/2/2026material
8-K — Executive/director change
SEC2/25/2026material
8-K — Results of operations, Exhibits
SEC1/27/2026material
8-K — Reg FD disclosure
SEC1/12/2026material

2025

8-K — Executive/director change
SEC11/21/2025material
8-K — Bylaw/charter change
SEC11/13/2025material
8-K — Reg FD disclosure
SEC11/7/2025material
8-K — Results of operations, Exhibits
SEC10/28/2025material
10-Q filing
SEC10/28/2025
8-K/A — Reg FD disclosure
SEC9/9/2025
8-K — Reg FD disclosure
SEC9/8/2025material
8-K — Reg FD disclosure
SEC8/20/2025material
10-Q filing
SEC8/11/2025
8-K — Executive/director change
SEC7/31/2025material
8-K — Results of operations, Exhibits
SEC7/29/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.